166 related articles for article (PubMed ID: 15677599)
1. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
Wassef AA; Winkler DE; Roache AL; Abobo VB; Lopez LM; Averill JP; Mian AI; Overall JE
Am J Psychiatry; 2005 Feb; 162(2):330-9. PubMed ID: 15677599
[TBL] [Abstract][Full Text] [Related]
2. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study.
Zarate CA; Tohen M; Narendran R; Tomassini EC; McDonald J; Sederer M; Madrid AR
J Clin Psychiatry; 1999 Apr; 60(4):232-6. PubMed ID: 10221283
[TBL] [Abstract][Full Text] [Related]
3. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
Sherr JD; Kelly DL
Psychiatr Serv; 1998 Oct; 49(10):1355-7. PubMed ID: 9779912
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
Puryear LJ; Kunik ME; Workman R
J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):234-7. PubMed ID: 8561838
[TBL] [Abstract][Full Text] [Related]
5. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
Smith MC; Centorrino F; Welge JA; Collins MA
Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
[TBL] [Abstract][Full Text] [Related]
6. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
Pierre-Louis SJ; Brannegan RT; Evans AT
Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
9. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
Centorrino F; Kelleher JP; Berry JM; Salvatore P; Eakin M; Fogarty KV; Fellman V; Baldessarini RJ
Am J Psychiatry; 2003 Jul; 160(7):1348-50. PubMed ID: 12832255
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
Horne RL; Cunanan C
J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
[TBL] [Abstract][Full Text] [Related]
11. Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder.
Dalkilic A; Diaz E; Baker CB; Pearsall HR; Woods SW
Psychiatr Serv; 2000 Sep; 51(9):1184-6. PubMed ID: 10970927
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder.
MacMillan CM; Withney JE; Korndörfer SR; Tilley CA; Mrakotsky C; Gonzalez-Heydrich JM
J Psychiatr Pract; 2008 May; 14(3):160-9. PubMed ID: 18520785
[TBL] [Abstract][Full Text] [Related]
13. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
Hirschfeld RM; Bowden CL; Vigna NV; Wozniak P; Collins M
J Clin Psychiatry; 2010 Apr; 71(4):426-32. PubMed ID: 20361904
[TBL] [Abstract][Full Text] [Related]
15. Extended-release divalproex sodium for mood stabilization.
Stoner SC; Dubisar BM; Lea JW; Marken PA; Ramlatchman LV; Reynolds JB
Pharmacotherapy; 2004 Sep; 24(9):1147-53. PubMed ID: 15460175
[TBL] [Abstract][Full Text] [Related]
16. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
17. Divalproex sodium vs. valproic acid: drug utilization patterns, persistence rates and predictors of hospitalization among VA patients diagnosed with bipolar disorder.
Iqbal SU; Cunningham F; Lee A; Wang S; Hamed A; Miller DR; Ren X; Kazis L
J Clin Pharm Ther; 2007 Dec; 32(6):625-32. PubMed ID: 18021341
[TBL] [Abstract][Full Text] [Related]
18. Divalproex in the treatment of migraine.
Freitag FG
Psychopharmacol Bull; 2003; 37 Suppl 2():98-115. PubMed ID: 15021865
[TBL] [Abstract][Full Text] [Related]
19. Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder.
Muzyk AJ; Candeloro CL; Christopher EJ
Gen Hosp Psychiatry; 2010; 32(5):560.e1-3. PubMed ID: 20851283
[TBL] [Abstract][Full Text] [Related]
20. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Reoux JP; Saxon AJ; Malte CA; Baer JS; Sloan KL
Alcohol Clin Exp Res; 2001 Sep; 25(9):1324-9. PubMed ID: 11584152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
